Home Xinyu Tech and Guoxin Youyi Sign Strategic Partnership to Build a Medical Big Data Service Platform

Xinyu Tech and Guoxin Youyi Sign Strategic Partnership to Build a Medical Big Data Service Platform

May 27, 2017 10:08 CST Updated 10:08

mmexport1495848386659.jpg


During the Guiyang Big Data Expo, Xinyu Information Technology (Shanghai) Co., Ltd. (hereinafter referred to as “Xinyu Tech”) and Guoxin Youyi Data Co., Ltd. (hereinafter referred to as “Youyi Data”) signed a strategic cooperation agreement. The two parties will integrate their respective core capabilities to jointly build the DPS Medical Big Data Innovation Platform solution, aiming to promote the application and development of the medical data industry.


Since the issuance of the "Guiding Opinions of the General Office of the State Council on Promoting and Regulating the Application and Development of Health and Medical Big Data" (Guo Ban Fa [2016] No. 47), the development and application of medical big data have advanced rapidly; however, this has also given rise to a contradiction inherent to the big data industry between data privacy security and data utilization.


This collaboration,Leveraging their respective professional expertise in the big data and medical research data sectors, both parties will jointly develop innovative DPS solutions across the DaaS, PaaS, and SaaS layers. These solutions will encompass various aspects, including secure data storage, data tiering and classification with sharing mechanisms, artificial intelligence, and applications in disease-specific vertical domains., meeting regulatory requirements at all levels and leading the development of specialized medical data processing technologies in China.


It is reported that the two parties will initially launch cooperation and applications in four areas on the jointly developed DPS Medical Big Data Platform: the “Research-Grade Medical Data Platform,” the “Genomic Data Standardized Storage and Analysis Platform,” the “Personal Health Data Bank,” and the “Pharmaceutical Industry Data Management Solution.”


The DPS Medical Big Data Platform is an effective solution to address the current fragmentation and siloed nature of medical data. Leveraging the extensive underlying technical expertise accumulated by U-Data in building platforms such as the “Government Information Sharing and Service Platform” for the State Information Center, it provides data encryption and tiered classification, thereby facilitating secure sharing and collaborative workflows among authorized users within specific regions. The PaaS layer will evolve into an open platform interface, enabling third-party healthcare service providers to develop innovative applications.


Research-Grade Medical Data Platform and Genomic Data Standardized Storage and Analysis PlatformDesigned for the current era of precision medicine, this platform provides data solutions tailored to the characteristics of hospital data management and regulatory requirements in China. It enables structured and standardized storage of clinical data, as well as genomic testing data in various formats, including BAM, FASTQ, and VCF. Furthermore, it offers integrated analysis of clinical big data and genomic data, supporting medical decision-making and scientific statistical analysis, ultimately benefiting both healthcare providers and patients.


Personal Health Data Bank: Based on individual authorization, it aggregates health-related data from different times and sources, as well as cross-industry data, to create a unified view and health profile. It provides risk assessment and behavioral intervention recommendations, promoting inclusive healthcare.


The pharmaceutical data solution is developed to meet the needs of enterprises in the pharmaceutical sector. By leveraging stratified and graded medical data, it helps companies establish real-world study data centers and academic management platforms for relevant drugs, thereby enhancing operational efficiency across various business areas—including marketing, after-sales service, scientific research, and new product development. This represents a practical application of DPS in the pharmaceutical industry.


U-Easy Data is a mixed-ownership company initiated by the State Information Center. As the actual operator of the State Information Center’s government-enterprise cooperation platform, it aggregates intellectual, data, and industrial resources to build and operate a big data trading platform, establish a nationwide data circulation network, and create a national-level big data industry base.


Youyi DataEstablished big data industrial bases for the National Information Center in multiple regions, integrating diverse resources to provide tenant organizations with office space, entrepreneurial guidance, training and exchange opportunities, top-level design consulting for big data startups, and investment and financing management services. It offers intellectual support and innovation and entrepreneurship services to governments and enterprises. Committed to building a data-driven innovation ecosystem, UData is dedicated to constructing its big data ecosystem and promoting the vigorous development of the big data industry.


Xinyu Technologyis a big data company focused on the healthcare sector, aiming to build a one-stop service platform for efficient data management in healthcare. Its business currently covers 25 provinces and municipalities across China, having established in-depth collaborations with hundreds of Grade A tertiary hospitals and their departments, and has helped process hundreds of thousands of research-grade oncology cases.


It is a corporate member of the Chinese Society of Clinical Oncology (CSCO), a member of CDISC, and a strategic partner of the China Anti-Cancer Association (CACA). It initiated the establishment of the CSCO Committee on Clinical Data Specialization, promoting the standardization and collaborative sharing of clinical research data. Its “Keyanbao” database has become the data standardization participant and the exclusive data platform for multiple academic organizations, including the Chinese Society of Clinical Oncology and the Chinese Gastrointestinal Tumor Surgery Alliance.